Skip to main content Skip to main navigation menu Skip to site footer
Case Report
Published: 2022-05-25

False hyperparathyroids secondary to biotin prolonged use: a case report

Municipal Service of the city of Paulista, Endocrinology department, Pernambuco, Brazil
Federal University of Pernambuco, Physiology and Pharmacology department, Pernambuco, Brazil
Primary hyperparathyroidism Parathyroid hormone Biotin

Abstract

A 55-year-old overweight female patient with elevated parathyroid hormone (PTH) levels, without any other major plasma biochemical abnormalities, and with normal vitamin D and calcium levels. The condition was suggestive of normocalcemic primary hyperparathyroidism. Bone densitometry and 24-hour calciuria were normal. After extensive investigation and possible referral for exploratory surgery, the patient reported continued and chronic use of biotin supplementation (2.5 mg per day). Repeated tests after discontinuing the use of vitamin B7 showed normal PTH levels without surgical or pharmacological interventions. Biotin supplementation associated with the use of this vitamin as a component of biological assays for hormone dosage can generate incorrect laboratory results, which puts medical conduct at risk with inaccurate diagnoses and unnecessary procedures. Although, different substances or emotional conditions can interfere with hormone dosages, one must consider the use of food supplements such as biotin since it can also generate unreliable results. Discontinuation of the use of biotin, in addition to the assessment of serum biotin levels prior to hormone dosing is necessary for a correct evaluation of serum PTH levels. This study was analyzed and approved by the Research Ethics Committee, and obtaining the Informed Consent Form according to CNS/CONEP Resolution 466/12.

References

  1. Blaine J, Chonchol M, and Levi M Renal Control of Calcium, Phosphate, and Magnesium Homeostasis Clin J Am Soc Nephrol. 2015 Jul 7; 10(7): 1257-1272. Published online 2014 Oct 6. doi: 10.2215/CJN.09750913
  2. Song L. Calcium and bone metabolism indices. Advances in clinical chemistry, 2017, 82. 1 – 46.
  3. Peissig K, Condie BG, Manley NR. Endocrinol. Metab. Clin. North. Am, 2018, 47(4), 733-742.
  4. Guilmette J, Sadow PM. Parathyroid Pathology. Surg Pathol Clin, 2019, 12(4):1007-1019.
  5. Fancy T, Gallagher D, Hornig JD. Surgical anatomy of the thyroid and parathyroid glands. Otolaryngol Clin North Am, 2010;43(2):221–7.
  6. Waghray A, Milas M, Nyalakonda K, Siperstein E.A. Falsely low parathyroid hormone secondary to biotin interference: a case series Endocr Pract May-Jun 2013;19(3):451-5.doi: 10.4158/EP12158.OR
  7. Silva BC, Bilezkian. Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol,2015, 22, 41-50.
  8. Egbuna OI, Brown EM. Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol. 2008; 22:129–148.
  9. Fraser WD. Hyperparathyroidism. The Lancet. 2009, 374(9684), 145-58.
  10. Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. The Lancet. 2019, 391(10116), 168-178.
  11. Rosner I, Rogers E, Maddrey A, et al. Clinically Significant Lab Errors due to Vitamin B7 (Biotin) Supplementation: A Case Report Following a Recent FDA Warning. Cureus, 2019, 11(8): e5470. doi:10.7759/cureus.5470.
  12. Insogna KL. Primary hyperparathyroidism. N. Engl. J. Med. 2018, 379(11), 1050-1059.
  13. Oberger Marques JVO, Moreira CA. Primary hyperparathyroidism. Best Pract Res Clin Rheymatol. 2020, 34(3), 101514.
  14. Eufrazino C, Veras A, Bandeira F. Epidemiology of primary hyperparathyroidism and its non-classical manifestations in the city of Recife, Brazil. Clin. Med. Insights Endocrinol Diabetes. 2013, 6, 69-74.
  15. Dawood NB, Yan KL, Shien A, Livhits MJ, Yeh MW, Leung AM. Cliniical Endocrinology. 2020, 93:519-527.
  16. Bilezikian JP, Silverberg SH. N Engl J Med. 2004, 350, 1746-1751.
  17. Al-Salameh A, Becquemont L, Brailly-Tabard S, Aubourg P, Chanson P. A Somewhat Bizarre Case of Graves Disease Due to Vitamin Treatment. J Endocr Soc. 2017 Mar 23;1(5):431-435. doi: 10.1210/js.2017-00054. PMID: 29264498; PMCID: PMC5686664.
  18. Zempleni J, Kuroishi T. 2012. Biotin. 3(2), 213-214.
  19. Holmes EW, Samarasinghe S, Emanuele MA, Meah F: Biotin interference in clinical immunoassays: a cause for concern. Arch Pathol Lab Med. 2017, 141:1459-1460.

How to Cite

Neves, G., & Lira, E. C. (2022). False hyperparathyroids secondary to biotin prolonged use: a case report. International Journal of Nutrology, 15(2). https://doi.org/10.54448/ijn22207